Literature DB >> 8742225

Tissue distribution and pharmacokinetics of centchroman. A new nonsteroidal postcoital contraceptive agent and its 7-desmethyl metabolite in female rats after a single oral dose.

J K Paliwal1, R C Gupta.   

Abstract

This study reports assay methodology, tissue distribution, and the basic pharmacokinetic behavior of centchroman and its 7-desmethyl metabolite [7-desmethyl centchroman (DMC)] after a single 12.5 mg/kg po dose in young female rats. Plasma, liver, lung, spleen, uterus, and adipose tissue were collected at various time intervals up to 14 days after dose. Reversed-phase HPLC, coupled with fluorescence detector, was used for simultaneous determination of centchroman and DMC in biosamples. The drug and metabolite were quantitated up to 2 and 5 ng/ml in plasma and 10 and 20 ng/g in tissues, respectively. The assay method was validated in terms of accuracy, precision, interassay, and intraassay variability, and was found to be reliable and reproducible. Peak centchroman levels in all of the tissues were found between 8-12 hr, whereas DMC peaks appeared between 8 and 24 hr, except that in liver the first peak of 1.2 micrograms/g appeared in the 1-hr sample. Tissue-to-plasma concentration ratios of centchroman were > 200 times in the lung; > 100 times in the spleen, liver, and adipose tissue; and > 40 times in the uterus at maxima in each tissue. Similarly, tissue concentrations of DMC were > 350 times in the lung, > 100 times in the liver and spleen, and > 25 times in the uterus and adipose tissue than in the plasma. High tissue-to-plasma concentration ratios of metabolites than the parent drug are indicative of its greater affinity for tissues. Terminal half-life of the centchroman and DMC in plasma were 24.1 and 36.6 hr, respectively. The mean residence time of centchroman was highest in the liver (78.4 hr), followed by the uterus (72.7 hr), adipose tissue (47.5 hr), lung (46 hr), spleen (44.1 hr), and plasma (37.7 hr). The mean residence time of DMC was also highest in the liver (133.7 hr), followed by the uterus (122 hr), adipose tissue (85.2 hr), lung (62.6 hr), spleen (62.6 hr), and plasma (48.2 hr).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8742225

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  3 in total

Review 1.  Anti-cancer potential of a novel SERM ormeloxifene.

Authors:  Rishi Kumar Gara; Vasudha Sundram; Subhash C Chauhan; Meena Jaggi
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

2.  Ormeloxifene efficiently inhibits ovarian cancer growth.

Authors:  Diane M Maher; Sheema Khan; Jordan L Nordquist; Mara C Ebeling; Nichole A Bauer; Lucas Kopel; Man Mohan Singh; Fathi Halaweish; Maria C Bell; Meena Jaggi; Subhash C Chauhan
Journal:  Cancer Lett       Date:  2014-10-13       Impact factor: 8.679

3.  Effect of centchroman coadministration on the pharmacokinetics of metformin in rats.

Authors:  Jawahar Lal; Girish K Jain
Journal:  Indian J Pharmacol       Date:  2010-06       Impact factor: 1.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.